No Longer Available EXPANDED_ACCESS NCT00931086

Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99 (LBRA99)

An Expanded Access Trial of Belimumab Antibody (Monoclonal Anti-BLyS Antibody) in Patients With Rheumatoid Arthritis (RA) Who Were Previously Treated Under HGS Protocol LBRA99

Sponsor: GlaxoSmithKline

Conditions Rheumatoid Arthritis

Interventions belimumab

Updated 8 times since 2017 Last updated: Oct 29, 2012 Started: Apr 30, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Rheumatoid Arthritis and is currently ongoing. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

No Longer Available
Jul 2024 — Sep 2024 [monthly]

No Longer Available
Jan 2021 — Jul 2024 [monthly]

No Longer Available
Jun 2018 — Jan 2021 [monthly]

No Longer Available
Apr 2018 — Jun 2018 [monthly]

No Longer Available

Phase: NA → None

▶ Show 3 earlier versions

Jul 2017 — Apr 2018 [monthly]

No Longer Available NA

Phase: PHASE4 → NA
Feb 2017 — Jul 2017 [monthly]

No Longer Available PHASE4
Jan 2017 — Feb 2017 [monthly]

No Longer Available PHASE4

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Human Genome Sciences Inc., a GSK Company

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orlando, United States